Sign in

Trial result ·

IncobotulinumtoxinA for Upper Limb Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study tested incobotulinumtoxinA, sold as Xeomin, for essential tremor. It looked at adults with tremor in the arm. There were 78 people, and 77 got treatment. Each person got shots into the muscles of their main arm. Some got the drug and some got a dummy shot. Neither the people nor the study team knew who got which. The main test was the size of wrist shaking after 6 weeks.

What they found

The main goal of the trial was not met. Wrist shaking went down in both groups by week 6. On this test, the numbers leaned toward the dummy shot. But that gap was not clear. On a test of arm tasks, the drug group did better. Quality of life scores also leaned toward the drug group. Daily tasks got better by about the same amount in both groups. On the whole, people coped well with the drug. No new or surprising safety issues were seen.

What it means for patients

The drug did not beat the dummy shot on the main test. The authors say it may help arm tasks and quality of life. They say these ideas must be checked in more studies. The safety results looked good, with no new concerns.

Why it is not certain yet

The main goal was not reached, so other results are less sure. The authors say the extra results only raise ideas to test. The quality of life change was not clear enough to rule out chance. The abstract gives results up to week 6 only. More research is needed to confirm what was seen.

Source

IncobotulinumtoxinA for Upper Limb Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Trial.

PubMed · PMID 42931526

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Essential tremor publications